This session will discuss biosimilars, their mechanism of action, and how to incorporate their use in patient treatments. Focus will be drawn on cost benefits and challenges encountered related to approval of biosimilars and how creation of more biosimilars will affect the pharmaceutical landscape.

Upon completion of the session, participants will be able to:

Define what is considered a biosimilar
Discuss biosimilars’ mechanism of action
Increase awareness on when incorporating biosimilars into treatments plans is beneficial
Discuss the process of obtaining coverage and funding/coverage for biosimilars

Jim Koeller

Appearances